The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris Therapeutics, Inc. | COM | 00461U105 | 39,200 | 2,808,034 | SH | SOLE | 2,808,034 | 0 | 0 | ||
| Cymabay Therapeutics, Inc. | COM | 23257D103 | 5,272 | 1,787,094 | SH | SOLE | 1,787,094 | 0 | 0 | ||
| Kinnate Biopharma Inc. | COM | 49705R105 | 121,959 | 9,671,643 | SH | SOLE | 9,671,643 | 0 | 0 | ||
| Kura Oncology, Inc. | COM | 50127T109 | 33,910 | 1,849,947 | SH | SOLE | 1,849,947 | 0 | 0 | ||
| Lyell Immunopharma, Inc. | COM | 55083R104 | 86,600 | 13,282,181 | SH | SOLE | 13,282,181 | 0 | 0 | ||
| Nurix Therapeutics, Inc. | COM | 67080M103 | 8,579 | 677,143 | SH | SOLE | 677,143 | 0 | 0 | ||
| Pharvaris N.V. | COM | N69605108 | 71,757 | 3,246,926 | SH | SOLE | 3,246,926 | 0 | 0 | ||
| Quantum-Si Incorporated | COM CL A | 74765K105 | 4,109 | 1,771,249 | SH | SOLE | 1,771,249 | 0 | 0 | ||